Poster Oral Presentation 2

[PO-017] Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension

*Taku Kobayashi¹, Joana Torres², Randy Longman³, Konstantinos Katsanos⁴, Scott Lee⁵, Dominik Bettenworth⁶, Louis Korman⁷, Dimpy Mehra⁸, Norma Ruiz Santiago⁸, AnnKatrin Petersen⁸, Manik Desai⁸, Hsiuanlin Wu⁸, Dong Wang⁹, Mark T. Osterman⁸, Anjali Jain⁸, Bincy P. Abraham¹⁰ (1. Kitasato University Kitasato Institute Hospital, Tokyo, Japan, 2. Division of Gastroenterology, Hospital da Luz and Hospital Beatriz Angelo, Lisbon, Portugal; and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 3. Weill Cornell Medicine, New York, NY, USA, 4. Division of Gastroenterology, University of Ioannina, Ioannina, Greece, 5. Digestive Health Center, University of Washington Medical Center, Seattle, WA, USA, 6. University of Münster, Münster, Germany; and CED Schwerpunktpraxis, Münster, Germany, 7. Capital Digestive Care, Washington, DC, USA, 8. Bristol Myers Squibb, Princeton, NJ, USA, 9. Bristol Myers Squibb K. K., Tokyo, Japan, 10. Houston Methodist-Weill Cornell, Houston, TX, USA)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.